

SUPPLEMENTAL MATERIAL

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study

Jeffrey J. Crowley • Richard G. Langley • Kenneth B. Gordon • Andreas Pinter • Laura K. Ferris
• Simone Rubant • Huzefa Photowala • Zhenyi Xue • Tianshuang Wu • Tianyu Zhan • Stefan
Beeck • Megha Shah • Richard B. Warren

J. J. Crowley

Bakersfield Dermatology & Skin Cancer Medical Group, Bakersfield, CA, USA

R. G. Langley

Queen Elizabeth II Health Sciences Centre, Division of Dermatology, Department of Medicine,
Dalhousie University, Halifax, NS, Canada

K. B. Gordon

Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA

A. Pinter

Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt,
Frankfurt am Main, Germany

L. K. Ferris

Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, USA

S. Rubant

AbbVie Deutschland GmbH and Co KG, Ludwigshafen, Germany

H. Photowala • Z. Xue • T. Wu • T. Zhan • S. Beeck • M. Shah

AbbVie, Inc., North Chicago, IL, USA

R. B. Warren

The Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical
Research Centre, Manchester, UK

Table S1 Logistic regression models tested comparing proportion of patients achieving PASI 90 at week 52

Variables	p Value ^a
Model without interactions	
Age (< 40 years, 40 to < 65 years, ≥ 65 years)	0.7848
Sex (male, female)	0.1290
BMI (< 25 kg/m ² , 25 to < 30 kg/m ² , ≥ 30 kg/m ²)	0.2843
Baseline PASI (≤ median 18, > median 18)	0.3471
Treatment (risankizumab, secukinumab)	< 0.0001
Model with interactions ^b	> 0.05 ^c

BMI body mass index, *PASI* Psoriasis Area and Severity Index, *PASI 90* ≥ 90% improvement in PASI.

^aUnadjusted *p* values are reported for logistic regression models. The critical value with Bonferroni adjustment is 0.05 / 5 or 0.01 for the model without interactions and 0.05 / 11 or 0.0045 for the model with interactions.


^bInteractions include BMI and age, BMI and sex, BMI and baseline PASI, age and sex, age and baseline PASI, and sex and baseline PASI.

^c*p* values refer to the interaction terms in the model with interactions and all *p* values were not statistically significant.

Fig. S1 Clinical response over 52 weeks. Mean time to achieve clinical response over the 52-week study by PASI 90, PASI 100, and sPGA 0/1 (**a**). *p* values are based on a log-rank test. Number of study visits where patients maintained clinical response throughout week 16 to week 52 among those patients who achieved clinical response at week 16 (NRI, intent-to-treat population) (**b**). *Ns* are the number of patients with a particular response at week 16. *NRI* nonresponder imputation, *PASI 90/100* $\geq 90\%/100\%$ improvement in Psoriasis Area and Severity Index, *sPGA 0/1* static Physician's Global Assessment of clear (0) or almost clear (1), *95% CI* 95% confidence interval

Fig. S1

A



B

